Drug intelligence / Profile preview

ibrutinib + trastuzumab

Development stage: Unknown
Lead developer: Oncology Research
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Ibrutinib + trastuzumab is a combination therapy being investigated for HER2-positive breast cancer. This combination provides a two-pronged approach against breast cancer: trastuzumab works by blocking the ability of cancer cells to receive chemical signals that tell the cells to grow, while ibrutinib inhibits tumor growth by helping the body's immune system's T-cells and B-cells respond to the cancer. Previous studies have demonstrated that treatment with multiple HER2-directed drugs is more effective than single drug therapy, which is the rationale behind exploring this combination.

Other names: Imbruvica + Herceptin

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on ibrutinib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibrutinib + trastuzumab.

Explore the full profile